Literature DB >> 25374915

Potent increased risk of the initiation of DNA replication in human prostate cancer with the use of 5α-reductase inhibitors.

Takeo Kosaka1, Yota Yasumizu1, Yasumasa Miyazaki1, Akira Miyajima1, Eiji Kikuchi1, Mototsugu Oya1.   

Abstract

Recent clinical studies have raised the clinically important question of the relationship between dihydrotestosterone (DHT) and prostate cancer (PCa) progression. The significance of DHT or 5α-reductase inhibitors (5ARI) in PCa development and progression has not yet been fully characterized. The aim of this study was to determine whether the initiation of DNA replication was influenced by DHT in PCa. Three cell lines were used. LNCaP: a human PCa cell line that exhibits androgen-dependent proliferation, C4-2: a human PCa cell line that exhibits androgen-independent proliferation, and C4-2AT6: a castration resistant prostate cancer cell line. Two 5ARIs, finasteride and dutasteride, were used. We examined the mRNA expression of the components of pre-replication complex (Pre-RC), CDC6, CDT1, and MCM2-7. DHT induced cell proliferation of LNCaP accompanied by significantly increased CDC6, CDT1, and MCM2-7 expression. In contrast to LNCaP, DHT inhibited cell proliferation in C4-2AT6 cells accompanied by decreased expression of CDC6, CDT1, and MCM2-7. These reverse effects resemble the effects of 5ARIs in Pre-RC. Treatment with finasteride or dutasteride inhibited CDC6 expression in LNCaP, but both 5ARIs induced CDC6 expression in C4-2 and C4-2AT6 cells.These results indicate that DHT showed reversal effects on PCa cell proliferation among prostate cancer cells based on androgen-dependence, accompanied by regulation of the initiation of DNA replication. 5ARIs may modulate the DNA replication system in someaggressive PCa through up-regulation of CDC6 expression.

Entities:  

Keywords:  5α-reductase inhibitors; C4-2AT6; CDC6; Castration resistant prostate cancer; DNA replication; pre-replication complex

Year:  2014        PMID: 25374915      PMCID: PMC4219299     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN: 2330-1910


  25 in total

1.  Effect of dutasteride on the risk of prostate cancer.

Authors:  Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster
Journal:  N Engl J Med       Date:  2010-04-01       Impact factor: 91.245

2.  The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

Authors:  Marc R Theoret; Yang-Min Ning; Jenny J Zhang; Robert Justice; Patricia Keegan; Richard Pazdur
Journal:  N Engl J Med       Date:  2011-06-15       Impact factor: 91.245

3.  Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.

Authors:  Ivan V Litvinov; Donald J Vander Griend; Lizamma Antony; Susan Dalrymple; Angelo M De Marzo; Charles G Drake; John T Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

Review 4.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

Authors:  Howard I Scher; Charles L Sawyers
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

5.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

6.  Commentary on "Abiraterone in metastatic prostate cancer without previous chemotherapy." Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA. N Engl J Med 2013;368(2):138-48 [Epub 2012 Dec 10]; N Engl J Med 2013;368(6):584.

Authors:  Donald L Trump
Journal:  Urol Oncol       Date:  2013-11       Impact factor: 3.498

7.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Authors:  Jennifer A Locke; Emma S Guns; Amy A Lubik; Hans H Adomat; Stephen C Hendy; Catherine A Wood; Susan L Ettinger; Martin E Gleave; Colleen C Nelson
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

8.  Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer.

Authors:  Takeo Kosaka; Akira Miyajima; Suguru Shirotake; Eiji Kikuchi; Masanori Hasegawa; Shuji Mikami; Mototsugu Oya
Journal:  Prostate       Date:  2010-02-01       Impact factor: 4.104

9.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

10.  A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression.

Authors:  Feng Jin; Joseph D Fondell
Journal:  Nucleic Acids Res       Date:  2009-06-11       Impact factor: 16.971

View more
  4 in total

1.  Combination of 5α-reductase inhibitor with combined androgen blockade (CAB) as a novel cytoreductive regimen before prostate brachytherapy: Ultra-CAB.

Authors:  Yusuke Muro; Takeo Kosaka; Ryuichi Mizuno; Toshio Ohashi; Naoyuki Shigematsu; Mototsugu Oya
Journal:  Am J Clin Exp Urol       Date:  2015-04-25

Review 2.  Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.

Authors:  Jason M Hirshburg; Petra A Kelsey; Chelsea A Therrien; A Carlo Gavino; Jason S Reichenberg
Journal:  J Clin Aesthet Dermatol       Date:  2016-07-01

3.  Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.

Authors:  Jeri Kim; John W Davis; Eric A Klein; Cristina Magi-Galluzzi; Yair Lotan; John F Ward; Louis L Pisters; Joseph W Basler; Curtis A Pettaway; Andrew Stephenson; Elsa M Li Ning Tapia; Eleni Efstathiou; Xuemei Wang; Kim-Anh Do; J Jack Lee; Ivan P Gorlov; Lana A Vornik; Ashraful M Hoque; Ina N Prokhorova; Howard L Parnes; Scott M Lippman; Ian M Thompson; Powel H Brown; Christopher J Logothetis; Patricia Troncoso
Journal:  EBioMedicine       Date:  2016-04-07       Impact factor: 8.143

4.  Long non-coding RNA-PCGEM1 contributes to prostate cancer progression by sponging microRNA miR-129-5p to enhance chromatin licensing and DNA replication factor 1 expression.

Authors:  Qiao Fu; Fangfang Wang; Jun Yang; Wei Sun; Zhi Hu; Lv Xu; Hao Chu; Xiao Wang; Wei Zhang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.